| 15.59 Net Asset Value | +1.43% 1 Day | +29.70% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 0.95% Expense Ratio | Above Average Morningstar Risk Rating™ |
| 1 month | -2.74% | 3 years | +32.57% | |
| 3 months | +12.56% | 5 years | +18.67% | |
| 1 year | +43.75% | Since inception | +4.86% |
| FBTIX | Category | |
|---|---|---|
| Performance 5-yr return | +18.67% | +12.10% |
| Expense ratio | 0.95% | 1.54% |
| Risk 5 year sharpe ratio | 0.92 | 0.71 |
| Net assets | $505.7M | $1.6B |
| Average market cap | $12.5B | $19.5B |
| Average P/E | 25.2 | 21.7 |
| Portfolio turnover | 82% | 82% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Fidelity Investments |
| Fund manager & tenure | Rajiv Kaul / 7 Years |
| Minimal initial investment | $2,500.00 |
| Minimum IRA investment | $500.00 |
| Other | 100.00% |
| U.S. stock | -- |
| International stock | -- |
| Fixed income | -- |
| Cash | -- |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| AMGN Amgen Inc | 14.95% |
| GILD Gilead Sciences Inc | 14.14% |
| CELG Celgene Corporation | 7.50% |
| BIIB Biogen Idec Inc | 6.87% |
| ALXN Alexion Pharmaceuticals, Inc. | 5.41% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.59% |
| VRTX Vertex Pharmaceuticals | 4.54% |
| BMRN Biomarin Pharmaceutical, Inc. | 2.52% |
| ONXX Onyx Pharmaceuticals, Inc. | 2.24% |
| MDVN Medivation, Inc. | 1.92% |
.
